(NASDAQ: CLLS) Cellectis Sa's forecast annual revenue growth rate of 27.12% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.48%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.37%.
Cellectis Sa's revenue in 2025 is $49,217,000.On average, 1 Wall Street analysts forecast CLLS's revenue for 2025 to be $1,680,000,000, with the lowest CLLS revenue forecast at $1,680,000,000, and the highest CLLS revenue forecast at $1,680,000,000. On average, 1 Wall Street analysts forecast CLLS's revenue for 2026 to be $3,438,400,000, with the lowest CLLS revenue forecast at $3,438,400,000, and the highest CLLS revenue forecast at $3,438,400,000.
In 2027, CLLS is forecast to generate $2,357,600,000 in revenue, with the lowest revenue forecast at $2,357,600,000 and the highest revenue forecast at $2,357,600,000.